tiprankstipranks
Advertisement
Advertisement
Alterity Therapeutics Discloses Change in Substantial Shareholding in June 2026 SEC Filing
PremiumCompany AnnouncementsAlterity Therapeutics Discloses Change in Substantial Shareholding in June 2026 SEC Filing
21d ago
Alterity Therapeutics initiated with a Buy at JonesResearch
Premium
The Fly
Alterity Therapeutics initiated with a Buy at JonesResearch
22d ago
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
Premium
Company Announcements
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
1M ago
Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
PremiumCompany AnnouncementsAlterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
1M ago
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
Premium
The Fly
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
1M ago
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
Premium
Company Announcements
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
1M ago
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
PremiumCompany AnnouncementsAlterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
2M ago
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
Premium
The Fly
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
3M ago
Alterity Therapeutics presents new data analyses from ATH434 trial
Premium
The Fly
Alterity Therapeutics presents new data analyses from ATH434 trial
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100